Critical Care Antiarrhythmic Drugs Global Market Report 2024

Critical care antiarrhythmic drugs are medications utilized in critical care settings to manage life-threatening cardiac arrhythmias such as ventricular fibrillation and ventricular tachycardia. Administered intravenously, these drugs act swiftly to restore normal heart rhythm and prevent cardiac arrest, playing a crucial role in stabilizing patients with severe cardiac rhythm disturbances.

These drugs encompass several types including beta blockers, calcium channel blockers, sodium channel blockers, potassium channel blockers, and others. Beta blockers, for instance, function by blocking adrenaline effects, thereby lowering heart rate and blood pressure. They are employed across various settings such as hospitals, clinics, and ambulatory centers to treat conditions such as ventricular arrhythmias and supraventricular arrhythmias.

The critical care antiarrhythmic drug market research report is one of a series of new reports that provides critical care antiarrhythmic drug market statistics, including critical care antiarrhythmic drug industry global market size, regional shares, competitors with a critical care antiarrhythmic drug market share, detailed critical care antiarrhythmic drug market segments, market trends and opportunities, and any further data you may need to thrive in the critical care antiarrhythmic drug industry. This critical care antiarrhythmic drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The critical care antiarrhythmic drugs market size has grown strongly in recent years. It will grow from $0.95 billion in 2023 to $1.01 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. In the historical period, growth can be ascribed to factors such as increased prevalence of cardiac arrhythmias, expansion of critical care facilities, regulatory approvals and guidelines, rising healthcare expenditure, and public health initiatives aimed at cardiac care.

The critical care antiarrhythmic drugs market size is expected to see strong growth in the next few years. It will grow to $1.29 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The anticipated growth in the forecast period is driven by factors including the growing adoption of precision medicine, escalating incidence of cardiovascular diseases, development of healthcare infrastructure in emerging markets, regulatory approvals for new therapies, and heightened focus on patient safety and treatment efficacy. Key trends expected in this period encompass advancements in drug delivery technologies, innovations in cardiac monitoring technologies, integration of digital health solutions, a shift towards combination therapies, and increased focus on non-pharmacological interventions.

The rising prevalence of cardiovascular disease is expected to drive the growth of the critical care antiarrhythmic drugs market. Cardiovascular disease encompasses conditions affecting the heart or blood vessels, leading to complications such as heart attacks or strokes. Several factors contribute to the increasing prevalence of cardiovascular disease, including sedentary lifestyles, poor dietary habits, smoking, and rising rates of obesity and hypertension. Critical care antiarrhythmic drugs are crucial for managing life-threatening cardiac arrhythmias, restoring normal heart rhythm, and preventing cardiac arrest in patients with cardiovascular disease. For instance, according to the World Heart Federation, a Switzerland-based non-governmental organization, the burden of cardiovascular disease, measured by the number of CVD deaths, is projected to rise from an estimated 18.9 million in 2020 to over 22.2 million in 2030 and 32.3 million in 2050. Consequently, the increasing prevalence of cardiovascular disease is fueling the growth of the critical care antiarrhythmic drugs market.

Leading companies in the critical care antiarrhythmic drugs market are developing advanced products, such as the therapeutic equivalent of Mexitil, to gain a competitive advantage. Mexitil is an antiarrhythmic medication that stabilizes the heart's electrical activity by blocking sodium channels in cardiac tissues, helping regulate irregular heart rhythms such as ventricular arrhythmias. For example, in January 2022, Senores Pharmaceuticals Inc., a US-based pharmaceutical company, launched Mexiletine Hydrochloride Capsules USP in strengths of 150 mg, 200 mg, and 250 mg in the U.S. market. These capsules serve as a therapeutic alternative to MEXITIL (Mexiletine Hydrochloride) and are prescribed for managing confirmed ventricular arrhythmias, including sustained ventricular tachycardia, which pose life-threatening risks.

In April 2022, Melinta Therapeutics LLC, a US-based pharmaceutical company, acquired the U.S. rights to TOPROL-XL (metoprolol succinate) and its Authorized Generic (AG) from New American Therapeutics Inc. for an undisclosed amount. This acquisition expands and diversifies Melinta's existing portfolio and supports its long-term growth strategy and profitability. New American Therapeutics Inc. is a US-based specialty pharmaceutical company that provides critical-care antiarrhythmic drugs.

Major companies operating in the critical care antiarrhythmic drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., Bristol Myers Squibb, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals Plc, Amneal Pharmaceuticals Inc., Lupin Pharmaceutical Limited, Biocon Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Upsher-Smith Laboratories LLC., Mayne Pharma International Pty Ltd., Zydus Cadila Healthcare Limited, Amomed Pharma GmbH.

North America was the largest region in the critical care antiarrhythmic drugs market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the critical care antiarrhythmic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the critical care antiarrhythmic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The critical care antiarrhythmic drugs market consists of sales of drugs such as amiodarone, lidocaine, and procainamide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.